keyword
MENU ▼
Read by QxMD icon Read
search

erythema nodosum leprosum

keyword
https://www.readbyqxmd.com/read/29516895/reactive-perforating-leprosy-erythema-multiforme-like-reactions-sweet-s-syndrome-like-reactions-as-atypical-clinical-manifestations-of-type-2-leprosy-reaction
#1
Hendra Gunawan, Yuri Yogya, Risty Hafinah, Rachel Marsella, Devi Ermawaty, Oki Suwarsa
Type 2 leprosy reactions commonly known as erythema nodosum leprosum, but various clinical manifestations of type 2 leprosy reaction were exist. The highlight of this case series was to report various atypical clinical manifestations of type 2 leprosy reaction such as reactive perforating leprosy, erythema multiforme-like reaction, and sweet's syndrome (SS)-like reaction.
January 2018: International Journal of Mycobacteriology
https://www.readbyqxmd.com/read/29499046/complement-c1q-expression-in-erythema-nodosum-leprosum
#2
Edessa Negera, Stephen L Walker, Tsehainesh Lemma, Abraham Aseffa, Diana N Lockwood, Hazel M Dockrell
Complement C1q is a soluble protein capable of initiating components of the classical pathway in host defence system. In earlier qualitative studies, C1q has been implicated in the pathogenesis of Erythema Nodosum Leprosum (ENL). However, little is known about the role of this complement in ENL reaction. In the present study we described the protein level of C1q production and its gene expression in the peripheral blood and skin biopsies in patients with ENL reaction and lepromatous leprosy (LL) patient controls before and after treatment...
March 2, 2018: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29479352/the-effects-of-prednisolone-treatment-on-cytokine-expression-in-patients-with-erythema-nodosum-leprosum-reactions
#3
Edessa Negera, Stephen L Walker, Kidist Bobosha, Yonas Bekele, Birtukan Endale, Azeb Tarekegn, Markos Abebe, Abraham Aseffa, Hazel M Dockrell, Diana N Lockwood
Erythema nodosum leprosum (ENL) is a systemic inflammatory complication occurring mainly in patients with lepromatous leprosy (LL) and borderline lepromatous leprosy. Prednisolone is widely used for treatment of ENL reactions but clinical improvement varies. However, there is little good in vivo data as to the effect of prednisolone treatment on the pro-inflammatory cytokines in patients with ENL reactions. As a result, treatment and management of reactional and post-reactional episodes of ENL often pose a therapeutic challenge...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29474830/erythema-nodosum-leprosum-update-and-challenges-on-the-treatment-of-a-neglected-condition
#4
REVIEW
Perpétua do Socorro Silva Costa, Lucas Rosa Fraga, Thayne Woycinck Kowalski, Egon Luiz Rodrigues Daxbacher, Lavínia Schuler-Faccini, Fernanda Sales Luiz Vianna
Erythema Nodosum Leprosum (ENL) occurs due to the immunological complication of multibacillary leprosy and is characterized by painful nodules and systemic compromising. It is usually recurrent and/or chronic and has both physical and economic impact on the patient, being a very important cause of disability. In addition, ENL is a major health problem in countries where leprosy is endemic. Therefore, adequate control of this condition is important. The management of ENL aims to control acute inflammation and neuritis and prevent the onset of new episodes...
February 20, 2018: Acta Tropica
https://www.readbyqxmd.com/read/29403176/cytological-diagnosis-of-erythema-nodosum-leprosum-in-clinically-unsuspected-cases-a-report-of-two-cases
#5
Shruti Semwal, Deepti Joshi, Garima Goel, Neha Mittal, Kaushik Majumdar, Neelkamal Kapoor
Leprosy is a chronic infectious disease caused by Mycobacterium leprae. The manifestations of this disease varies across the spectrum of tuberculoid (TT) to lepromatous (LL) leprosy. The course of this indolent disease is interrupted by acute exacerbations in the form of leprare actions. Erythema nodosum leprosum (ENL), a type 2 lepra reaction, occurs in lepromatous or borderline lepromatous cases, usually in response to multidrug therapy. Early detection and timely management of these patients is important to reduce the associated morbidity...
January 2018: Journal of Cytology
https://www.readbyqxmd.com/read/29317571/erythema-nodosum-leprosum-necroticans
#6
Deepika Pandhi, Anita Kulhari
No abstract text is available yet for this article.
December 15, 2017: Indian Pediatrics
https://www.readbyqxmd.com/read/29315045/erythema-nodosum-leprosum
#7
Damian Bruce-Hickman, Adeline My Yong, Derrick Ac Wee, Nares Smitasin, Tan Kong Bin
No abstract text is available yet for this article.
January 2, 2018: British Journal of Hospital Medicine
https://www.readbyqxmd.com/read/29285050/thalidomide-and-its-analogues-a-review-of-the-potential-for-immunomodulation-of-fibrosis-diseases-and-opthalmopathy
#8
Ting Liu, Feng Guo, Xiaomin Zhu, Xiangge He, Lin Xie
The US Food and Drug Administration approved thalidomide and its analogues for the treatment of erythema nodosum leprosum, in spite of the notoriety of reports of severe birth defects in the middle of the last century. As immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases. In the present review, preclinical data about the effects of thalidomide and its analogues on the immune system are integrated, including the effects of cytokines on transdifferentiation, the anti-inflammatory effect, immune cell function regulation and angiogenesis...
December 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29204408/necrotic-erythema-nodosum-leprosum-healing-with-extensive-scars
#9
Chandra S Sirka, Maitreyee Panda, Swetalina Pradhan, Manas R Baisakh
No abstract text is available yet for this article.
November 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/29028793/clinico-pathological-features-of-erythema-nodosum-leprosum-a-case-control-study-at-alert-hospital-ethiopia
#10
Edessa Negera, Stephen L Walker, Selfu Girma, Shimelis N Doni, Degafe Tsegaye, Saba M Lambert, Munir H Idriss, Yohanis Tsegay, Hazel M Dockrell, Abraham Aseffa, Diana N Lockwood
BACKGROUND: Leprosy reactions are a significant cause of morbidity in leprosy population. Erythema nodosum leprosum (ENL) is an immunological complication affecting approximately 50% of patients with lepromatous leprosy (LL) and 10% of borderline lepromatous (BL) leprosy. ENL is associated with clinical features such as skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis and nephritis. ENL is treated mainly with corticosteroids and corticosteroids are often required for extended periods of time which may lead to serious adverse effects...
October 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29016342/case-report-histoplasmosis-in-himachal-pradesh-india-an-emerging-endemic-focus
#11
Vikram K Mahajan, Rashmi Kaul Raina, Suman Singh, Rattan Sagar Rashpa, Anuradha Sood, Pushpinder S Chauhan, Karaninder S Mehta, Ritu Rawat, Vikas Sharma
We describe four cases of histoplasmosis indigenous to Himachal Pradesh (India) that will be of considerable public health interest. A 48-year-old human immunodeficiency virus (HIV)-negative man with cervical and mediastinal lymphadenopathy, hepatosplenomegaly, adrenal mass, and bone marrow involvement was treated as disseminated tuberculosis without benefit. Progressive disseminated histoplasmosis was diagnosed from the fungus in smears from adrenal mass. Another 37-year-old HIV-positive man was on treatment of suspected pulmonary tuberculosis...
December 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28991896/t-cell-regulation-in-erythema-nodosum-leprosum
#12
Edessa Negera, Stephen L Walker, Kidist Bobosha, Rawleigh Howe, Abraham Aseffa, Hazel M Dockrell, Diana N Lockwood
Leprosy is a disease caused by Mycobacterium leprae where the clinical spectrum correlates with the patient immune response. Erythema Nodosum Leprosum (ENL) is an immune-mediated inflammatory complication, which causes significant morbidity in affected leprosy patients. The underlying cause of ENL is not conclusively known. However, immune-complexes and cell-mediated immunity have been suggested in the pathogenesis of ENL. The aim of this study was to investigate the regulatory T-cells in patients with ENL...
October 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28969152/azathioprine-in-chronic-recalcitrant-erythema-nodosum-leprosum-a-case-report
#13
Singh Shailendra Vikram Jitendra, Romita Bachaspatimayum, A Subhalakshmi Devi, S Rita
Erythema Nodosum Leprosum (ENL) may have a chronic course which may be recalcitrant to treatment. Preferred treatment modalities are systemic corticosteroids and thalidomide. Azathioprine, methotrexate and cyclosporine are immunosuppressants which may also be used as a steroid sparing agent. We report the case of a 48-year-old male diagnosed as lepromatous leprosy that developed ENL after four months of Multibacillary Multi-Drug Therapy (MB-MDT). He was treated with oral prednisolone (1 mg/kg/day) which was gradually tapered upto a dose of 7...
August 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28966621/new-insight-into-the-pathogenesis-of-erythema-nodosum-leprosum-the-role-of-activated-memory-t-cells
#14
Edessa Negera, Kidist Bobosha, Stephen L Walker, Birtukan Endale, Rawleigh Howe, Abraham Aseffa, Hazel M Dockrell, Diana N Lockwood
Memory T-cells, particularly, effector memory T cells are implicated in the pathogenesis of inflammatory diseases and may contribute to tissue injury and disease progression. Although erythema nodosum leprosum (ENL) is an inflammatory complication of leprosy, the role of memory T cell subsets has never been studied in this patient group. The aim of this study was at investigate the kinetics of memory T cell subsets in patients with ENL before and after prednisolone treatment. A case-control study design was used to recruit 35 untreated patients with ENL and 25 non-reactional lepromatous leprosy (LL) patient controls at ALERT Hospital, Ethiopia...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28954119/etanercept-in-erythema-nodosum-leprosum
#15
Julia Rocha Silva Santos, Dâmia Leal Vendramini, José Augusto da Costa Nery, João Carlos Regazzi Avelleira
One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept...
July 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28944149/a-case-of-leprosy-erythema-nodosum-leprosum-and-hemophagocytic-syndrome-a-continuum-of-manifestations-of-same-agent-host-interactions
#16
Prasan Kumar Panda, Ramjas Prajapati, Arvind Kumar, Manisha Jana, Pradeep Immanuel, Pranay Tanwar, Naveet Wig
A young adult man with 4-years history of lepromatous leprosy (received irregularly multidrug therapy) presented with two and half years history of symptoms suggestive of chronic erythema nodosum leprosum (ENL), initially responded to steroids and thalidomide, but later on failed. During the last 2-months, he developed fever, vomiting, and subsequently altered sensorium. On evaluation, he had hepatosplenomegaly, hyponatremia, hyperferritinemia, hemophagocytosis in bone marrow aspiration, lobular panniculitis in skin biopsy, and multiple parenchymal nodules in chest imaging...
August 2017: Intractable & Rare Diseases Research
https://www.readbyqxmd.com/read/28875310/simultaneous-analysis-of-multiple-t-helper-subsets-in-leprosy-reveals-distinct-patterns-of-th1-th2-th17-and-tregs-markers-expression-in-clinical-forms-and-reactional-events
#17
Michelle de Campos Soriani Azevedo, Heloisa Marques, Larissa Sarri Binelli, Mariana Silva Vieira Malange, Amanda Carreira Devides, Eliane Aparecida Silva, Luciana Raquel Vincenzi Fachin, Cassio Cesar Ghidella, Cleverson Teixeira Soares, Gustavo Pompermaier Garlet, Patrícia Sammarco Rosa, Andrea de Farias Fernandes Belone, Ana Paula Favaro Trombone
Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Previous studies have demonstrated that the difference among clinical forms of leprosy can be associated with the immune response of patients, mainly by T helper (Th) and regulatory T cells (Tregs). Then, aiming at clarifying the immune response, the expression of cytokines related to Th1, Th2, Th17 and Tregs profiles were evaluated by qPCR in 87 skin biopsies from leprosy patients. Additionally, cytokines and anti-PGL-1 antibodies were determined in serum by ELISA...
December 2017: Medical Microbiology and Immunology
https://www.readbyqxmd.com/read/28763338/bullous-erythema-nodosum-leprosum-as-the-first-manifestation-of-multibacillary-leprosy-a-rare-phenomenon
#18
Neha Bakshi, Seema Rao, Rohit Batra
Erythema nodosum leprosum (ENL) may uncommonly present before treatment in patients with multibacillary leprosy. Atypical manifestations are known in ENL and may be clinically misleading. Such wide variations in the clinical presentation of leprosy in reaction make histopathology an important tool for supporting clinical diagnosis. We report bullous ENL presenting as the first manifestation of leprosy in a 30-year-old Indian man diagnosed using histopathology.
November 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28719256/therapeutic-dilemma-of-refractory-erythema-nodosum-leprosum
#19
Jianyu Zhu, Degang Yang, Chao Shi, Zhichun Jing
AbstractErythema nodosum leprosum (ENL), also known as type II leprosy reaction, is a severe immune-mediated complication of multibacillary leprosy. For ENL, corticosteroids and thalidomide are the mainstays of treatment. Other immunosuppressants, such as clofazimine, cyclosporine, and azathioprine have also been used. Although most patients with ENL respond well to conventional treatments, a small number are refractory to these therapies and have severe morbidity or mortality. We report the case of a 24-year-old man with refractory ENL treated with high-dose corticosteroids for 15 months...
June 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28671966/a-leprosy-clinical-severity-scale-for-erythema-nodosum-leprosum-an-international-multicentre-validation-study-of-the-enlist-enl-severity-scale
#20
MULTICENTER STUDY
Stephen L Walker, Anna M Sales, C Ruth Butlin, Mahesh Shah, Armi Maghanoy, Saba M Lambert, Joydeepa Darlong, Benjamin Jewel Rozario, Vivek V Pai, Marivic Balagon, Shimelis N Doni, Deanna A Hagge, José A C Nery, Kapil D Neupane, Suwash Baral, Biliom A Sangma, Digafe T Alembo, Abeba M Yetaye, Belaynesh A Hassan, Mohammed B Shelemo, Peter G Nicholls, Diana N J Lockwood
OBJECTIVES: We wished to validate our recently devised 16-item ENLIST ENL Severity Scale, a clinical tool for measuring the severity of the serious leprosy associated complication of erythema nodosum leprosum (ENL). We also wished to assess the responsiveness of the ENLIST ENL Severity Scale in detecting clinical change in patients with ENL. METHODS: Participants, recruited from seven centres in six leprosy endemic countries, were assessed using the ENLIST ENL Severity Scale by two researchers, one of whom categorised the severity of ENL...
July 2017: PLoS Neglected Tropical Diseases
keyword
keyword
112953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"